NECA Reassesses HIPEC
HIPEC for Three Peritoneal Cancer Conditions Moves to Essential Coverage
Selective Coverage Maintained for Peritoneal Carcinomatosis Originating from Colorectal Cancer and Other Conditions

A treatment that circulates heated chemotherapy drugs inside the abdominal cavity after removing tumors in patients with peritoneal cancer may extend survival or lower the risk of death in certain conditions, including peritoneal carcinomatosis originating from ovarian cancer. However, the evidence supporting its effectiveness is insufficient for some conditions, and the findings indicate that patients should be selected for treatment based on their condition and tumor characteristics.


HIPEC Shows Potential to Improve Survival in Ovarian Cancer-Related Peritoneal Carcinomatosis and Mesothelioma View original image

The National Evidence-based Healthcare Collaborating Agency (NECA) announced on October 12 the results of a reassessment of the medical technology known as hyperthermic intraperitoneal chemotherapy (HIPEC), which is used in patients with peritoneal cancer. The assessment analyzed 117 studies and compared the safety and effectiveness of combining cytoreductive surgery with HIPEC against existing treatments.


HIPEC is performed after cytoreductive surgery, which removes as much visible tumor as possible, to eliminate any remaining microscopic cancer cells. The procedure circulates a chemotherapy solution heated to approximately 41 to 43 degrees Celsius inside the abdominal cavity for a set period. HIPEC underwent a new medical technology assessment in 2013 and was listed as a selectively covered benefit in 2021. The current reassessment was conducted as part of the regular review cycle for selective coverage.


The assessment covered five conditions: peritoneal carcinomatosis originating from ovarian cancer; peritoneal carcinomatosis originating from colon or rectal cancer; pseudomyxoma peritonei originating from appendiceal mucinous neoplasms; malignant peritoneal mesothelioma; and desmoplastic small round cell tumors.


The assessment found that combining cytoreductive surgery with HIPEC may extend survival to some extent or lower the risk of death in three conditions: peritoneal carcinomatosis originating from ovarian cancer, pseudomyxoma peritonei originating from appendiceal mucinous neoplasms, and malignant peritoneal mesothelioma.


For peritoneal carcinomatosis originating from colon or rectal cancer and desmoplastic small round cell tumors, some potential survival benefits were reported. However, study results were inconsistent or evidence for comparison with existing treatments was limited. The assessment therefore concluded that there was insufficient evidence to determine the treatment's effectiveness conclusively.


In terms of safety, cytoreductive surgery may involve extensive removal of abdominal organs and carries a risk of moderate or more severe complications. However, the procedure was assessed as suitable for clinical use if appropriate patients are selected at specialized medical institutions and it is performed by experienced medical staff.


Following amendments to the relevant notice reflecting the reassessment results, HIPEC for three conditions—peritoneal carcinomatosis originating from ovarian cancer, pseudomyxoma peritonei originating from appendiceal mucinous neoplasms, and malignant peritoneal mesothelioma—has been moved from selective coverage to essential coverage. Selective coverage with a 50% patient copayment will remain in place for peritoneal carcinomatosis originating from colon or rectal cancer and desmoplastic small round cell tumors.



Kim Minjeong, head of NECA's Healthcare Assessment and Research Division, said, "This reassessment confirmed that HIPEC may help improve survival for some patients with peritoneal cancer. We hope the findings will serve as an objective basis for determining appropriate treatment approaches that take into account patients' clinical conditions and the characteristics of their diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing